[Anti-IL-6 : new therapeutic trends], PMID: 28703549
[Experience of olokizumab use in COVID-19 patients], PMID: 33720587
[IL-6 blockade], PMID: 27311186
Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment, PMID: 33142700
Antibodies to watch in 2021, PMID: 33459118
Biosensing Cytokine IL-6: A Comparative Analysis of Natural and Synthetic Receptors, PMID: 32847008
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling, PMID: 24670876
Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial, PMID: 26358841
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study, PMID: 24641941
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis, PMID: 32033937
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future, PMID: 25648633
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab, PMID: 24833786
Interleukin-6 blocking agents for treating COVID-19: a living systematic review, PMID: 33734435
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond, PMID: 31523783
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies, PMID: 34101570
Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab, PMID: 24941311
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study, PMID: 34344706
Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases, PMID: 26982101
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis, PMID: 28579757
Rheumatoid arthritis: new monoclonal antibodies, PMID: 29771256
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study, PMID: 27129012
Targeting interleukin-6 for noninfectious uveitis, PMID: 26392750
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment., PMID:39919910
EFFICACY AND SAFETY OF OLOKIZUMAB IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS- A SYSTEMATIC REVIEW AND META-ANALYSIS., PMID:39585284
Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study., PMID:39441547
Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis., PMID:39198829
Identification of critical genes and metabolic pathways in rheumatoid arthritis and osteoporosis toward drug repurposing., PMID:39079412
Inflammation-mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis., PMID:38984761
Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic., PMID:38955912
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment., PMID:38955475
Efficacy of Olokizumab against Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of the Study., PMID:38861142
Text Mining and Drug Discovery Analysis: A Comprehensive Approach to Investigate Diabetes-Induced Osteoporosis., PMID:38250601
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?, PMID:37989892
Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials., PMID:37266677
Interleukin-6 blocking agents for treating COVID-19: a living systematic review., PMID:37260086
[Clinical cases of complicated diverticulitis against the background of severe course COVID-19. Case report]., PMID:37167171
NEUROPROTECTIVE AND ANTIOXIDANT POTENTIAL OF MONTELUKAST-ACETYLCYSTEINE COMBINATION THERAPY FOR BRAIN PROTECTION IN PATIENTS WITH COVID-19 INDUCED PNEUMONIA., PMID:37042600
Targeting Olokizumab-Interleukin 6 interaction interface to discover novel IL-6 inhibitors., PMID:36995131
Identification of potential molecular mechanisms and candidate drugs for radiotherapy- and chemotherapy-induced mucositis., PMID:36939936
The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis., PMID:36792848
Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials., PMID:36607422
Olokizumab's Effectiveness and Safety in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials., PMID:36535857
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis., PMID:36368906
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study., PMID:36109142
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis., PMID:36001712
Drug discovery in spinal cord injury-induced osteoporosis: a text mining-based study., PMID:35957736
Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis., PMID:35455757
A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential., PMID:35126375
Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19., PMID:34565057
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study., PMID:34344706
What do we know about IL-6 in COVID-19 so far?, PMID:37287491
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies., PMID:34101570
Interleukin-6 blocking agents for treating COVID-19: a living systematic review., PMID:33734435
[Experience of olokizumab use in COVID-19 patients]., PMID:33720587
Antibodies to watch in 2021., PMID:33459118
Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment., PMID:33142700
Biosensing Cytokine IL-6: A Comparative Analysis of Natural and Synthetic Receptors., PMID:32847008
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis., PMID:32033937
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond., PMID:31523783
Rheumatoid arthritis: new monoclonal antibodies., PMID:29771256
[Anti-IL-6 : new therapeutic trends]., PMID:28703549
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis., PMID:28579757
[IL-6 blockade]., PMID:27311186
Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases., PMID:26982101
Targeting interleukin-6 for noninfectious uveitis., PMID:26392750
Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial., PMID:26358841
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future., PMID:25648633
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study., PMID:27129012
Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab., PMID:24941311
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab., PMID:24833786
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling., PMID:24670876
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study., PMID:24641941
For research use only. Not for human or drug use.
